Antje M. Wengner

Differential Mobilization of Subsets of Progenitor Cells from the Bone Marrow

Simon C. Pitchford, Rebecca C. Furze, Carla P. Jones et al. · Cell stem cell · 2009 · 282 citations · Full text

Progenitor Cells, Bone Marrow Failure, Health Sciences +11

The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation

Antje M. Wengner, Simon C. Pitchford, Rebecca C. Furze et al. · Blood · 2007 · 224 citations · Full text

Chemokine Biology, Immunology, Immunologic Mechanism +19

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 200 citations

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (<i>R</i>)‐<i>S</i>‐Cyclopropyl‐<i>S</i>‐(4‐{[4‐{[(1<i>R</i>,2<i>R</i>)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Ulrich Lücking, Rolf Jautelat, Martin Krüger et al. · ChemMedChem · 2013 · 173 citations

Aminopyrimidine Zk 304709, Lab Oddity Prevails, Lead Identification +21

BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner et al. · Molecular Cancer Therapeutics · 2012 · 154 citations · Full text

Oral Application, Chemoprevention Strategy, Retinoblastoma Protein +19